Search Results
Your search for ,SeT matches 2143 pages
Showing 351 - 400Genome Sequencing of Circulating Tumor Cells in Detection of Myeloma and Precursor Conditions
The novel MinimuMM-seq technique may make it possible to detect tumor cells in individuals at higher risk for multiple myeloma, assess the risk of disease progression in patients with myeloma, and track genetic changes in tumor cells over time from a single blood sample, according to a new study...
Clinical Trial Lab-Based Eligibility Criteria Disproportionately Excluded Non-White Patients With DLBCL From Study Participation
A previous analysis by Khurana et al on the impact of inclusion/exclusion criteria in clinical trial design for patients with diffuse large B-cell lymphoma (DLBCL) found that up to 24% of patients treated with standard immunochemotherapy were excluded based on five lab-based criteria alone. A new...
Andrew Matthews, MD, on AML: Real-World Effectiveness of 7 + 3 Intensive Chemotherapy vs Venetoclax and a Hypomethylating Agent
Andrew Matthews, MD, of the Abramson Cancer Center, University of Pennsylvania, discusses findings from a large, multicenter study that showed superior outcomes with 7 + 3 chemotherapy (cytarabine continuously for 7 days, along with short infusions of an anthracycline on each of the first 3 days)...
Heartbreak and a Second Chance at Love and Life
“I knew my husband was dying in June. He’d been living with a terminal diagnosis for 6 years, but suddenly his cancer turned aggressive…. The last time we saw the oncologist, he sent us home with a DNR order and told me to put it on the refrigerator, because that’s where the EMTs look,” writes...
Sexual Side Effects of Radiotherapy for Genitourinary Cancers: Is Physician Assessment Equitable for Women and Men?
Many radiation oncologists tend to discuss the sexual side effects of radiation therapy, specifically brachytherapy, with men more often than with women, according to a two-part study reported at the 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting.1 At a high-volume cancer...
How the Pancreatic Cancer Early Detection Consortium Aims to Advance Survival Rates in This Deadly Disease
The statistics are grim: Worldwide, pancreatic cancer is the 12th most common cancer and the seventh leading cause of cancer mortality.1 In the United States, the malignancy has the highest mortality rate of all major cancers. It is currently the third leading cause of cancer-related death after...
Epigenetic Imprinted Biomarker Test to Identify Malignant Thyroid Nodules
In a Chinese study reported in the Journal of Clinical Oncology, Xu et al found that a test for epigenetic imprinted biomarkers was highly accurate in distinguishing malignant vs benign thyroid nodules. Study Details The multicenter study involved 550 consecutively enrolled patients with nodules...
High Deductibles May Discourage Patients From Receiving Additional Testing After an Abnormal Mammogram
Twenty percent of patients are likely to forgo additional testing after an abnormal finding on a screening mammogram if there is a deductible, according to new findings presented at the Radiological Society of North America (RSNA) 2022 Annual Meeting. Background As health-care costs and insurance...
Incidence of Cervical Cancer in Women in the United States: 2001 to 2019
In a study reported as a research letter in JAMA, Shahmoradi et al found that the incidence of cervical cancer decreased or remained stable in U.S. women between 2001 and 2019, except for an increase in the 30- to 34-year-old age group in more recent years. As stated by the investigators, “A recent ...
High Sugar Consumption May Be Linked to Increased Risk of Premature Aging in Pediatric Cancer Survivors
Survivors of pediatric cancer who consumed more total sugar, added sugar, and sugar-sweetened beverages had more aging-related health conditions than survivors who consumed less sugar, according to a new study presented by Lan et al at the American Association for Cancer Research (AACR) Special...
C.S. Pramesh, MS, FRCS, Seeks to Bring Equity to India’s Sprawling Cancer Care System
In this installment of The ASCO Post’s Living a Full Life series, Guest Editor Jame Abraham, MD, FACP, spoke with C.S. Pramesh, MS, FRCS, Director of the Tata Memorial Hospital and Professor and Head of Thoracic Surgery at the Tata Memorial Centre, Mumbai, India. Dr. Pramesh is the Convener of the...
UICC Outlines Antimicrobial Resistance in Cancer Treatment
Marking World Antimicrobial Awareness Week (taking place November 18 to 24), the Union for International Cancer Control (UICC) emphasized the danger that drug resistance poses to individuals who are particularly vulnerable to infection, such as people living with cancer. There has been substantial...
First-Line Maintenance Therapy With Olaparib Improved Outcomes in BRCA-Mutated, HRD-Positive Advanced Ovarian Cancer
First-line maintenance therapy with olaparib extended survival beyond historical expectations in some women with newly diagnosed advanced ovarian cancer, according to long-term follow-up of two phase III studies presented at the European Society for Medical Oncology (ESMO) Congress 2022.1,2 Paul...
Researchers Find Changes in Blood Proteins up to 2 Years Before Breast Cancer Diagnosis
Researchers have found changes in the levels of particular proteins in patients’ blood up to 2 years before they were diagnosed with breast cancer, according to a novel study published by Hagenaars et al in the European Journal of Cancer. The study, also presented at the 13th European Breast Cancer ...
Study Examines Potential Factors Leading to Recurrence of Cancers Caused by BRCA Mutations
Researchers have discovered the factors that may make breast and ovarian cancers associated with BRCA1 and BRCA2 gene mutations more likely to recur, according to new findings published by Shah et al in Nature Communications. These mutations are known to strongly predispose women to breast and...
Study Shows That Immune Cells May Help Identify Patients With High-Risk Smoldering Myeloma Most Likely to Benefit From Treatment
For many patients who have smoldering myeloma, early treatment can slow or delay the disease’s progression to multiple myeloma, according to a new study published by Sklavenitis-Pistofidis et al in Cancer Cell. Investigators demonstrated that changes in immune system cells may indicate which cases...
Used as a Biomarker, MicroRNA May Help Predict Which Patients With Breast Cancer Are More Likely to Have Cancer Recurrence
MicroRNA may be used as a biomarker to predict which patients are likely to face breast cancer recurrence and mortality, according to a new study published by Davey et al in the Journal of the American College of Surgeons. While long-term outcomes have improved for patients with breast cancer, 20%...
New Research Highlights Disparities in Receipt of Guideline-Concordant Treatment Among Patients With Ovarian Cancer
New research examining whether patients with ovarian cancer were receiving care concordant with the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines) found clear disparities based on patients’ race, ability to pay, and access to specialists and...
POSEIDON Follow-up Suggests Chemoimmunotherapy Triplet Extends Survival in Difficult-to-Treat NSCLC Mutational Subtypes
After 4 years, a limited course of five cycles of tremelimumab added to durvalumab plus chemotherapy extended overall survival in patients with metastatic non–small cell lung cancer (NSCLC) compared with chemotherapy alone, according to an updated exploratory analysis of the phase III POSEIDON...
How to Advance Antiracist Approaches to Patient Engagement in AYA Oncology and Research
Among the topics discussed at the 4th Global Adolescent and Young Adult Cancer Congress held online in December 2021 was the urgent need for clinicians, researchers, and advocates in adolescent and young adult (AYA) oncology to join forces to eradicate racist approaches to patient engagement in...
Expert Point of View: Mary O’Brien, MD
Formal discussant Mary O’Brien, MD, Head of the Lung Unit, the Royal Marsden Hospital, NHS Foundation Trust, London, commented on the POSEIDON trial. “The POSEIDON trial is the largest data set we have on KRAS-mutated [non–small cell lung cancer], with a positive signal in picking up some patients...
2022 Annual Report to the Nation on the Status of Cancer Released
Overall cancer death rates continued to decline among men, women, children, adolescents, and young adults in every major racial and ethnic group in the United States from 2015 to 2019, according to the latest Annual Report to the Nation on the Status of Cancer. From 2014 to 2018, overall cancer...
Leader in Genitourinary Oncology, Nicholas J. Vogelzang, MD, FACP, FASCO, Dies at 72
Nicholas J. Vogelzang, MD, FACP, FASCO, an expert in the treatment of patients with renal cell carcinoma, died on September 20, 2022. Dr. Vogelzang was 72 years old. Son of a Preacher Dr. Vogelzang was born on December 13, 1949, in Holland, Michigan, the oldest of seven children, in a close-knit...
Providing a Tailored Approach to Prostate Cancer Care for Gay and Bisexual Men
It is estimated that one in eight men will be diagnosed with prostate cancer in his lifetime. The disease is so prevalent, and other than skin cancer, it is the most common cancer diagnosed in American men. According to the American Cancer Society, this year, about 268,490 new cases of prostate...
MONALEESA Analyses Show Widespread Benefit for Ribociclib in Hormone Receptor–Positive, HER2-Negative Breast Cancer
Further analyses of the MONALEESA metastatic breast cancer trials have shown that the benefit of ribociclib plus endocrine therapy in the first-line setting extends to most intrinsic molecular subtypes and is consistent across multiple subgroups. The studies were presented at the 2021 San Antonio...
Expert Point of View: Debu Tripathy, MD, and Hope S. Rugo, MD, FASCO
The ASCO Post asked Debu Tripathy, MD, Professor and Chair of Medical Breast Oncology at The University of Texas MD Anderson Cancer Center, Houston, and Hope S. Rugo, MD, FASCO, Professor of Medicine, Director of Breast Oncology and Clinical Trials Education at the University of California San...
Strides Are Being Made in the Treatment of Brain Metastases From Breast Cancer
New drugs for HER2-positive breast cancer are able to overcome some of the obstacles that have made brain metastases challenging to treat, according to Mark Pegram, MD, the Susy Yuan-Huey Hung Professor of Oncology at Stanford University School of Medicine in California, who described the promising ...
First-Line Maintenance With Olaparib Improved Overall Survival in Subsets of Patients With Advanced Ovarian Cancer in Two Phase III Trials
First-line maintenance therapy with olaparib extended survival beyond historical expectations in some women with newly diagnosed advanced ovarian cancer, according to two phase III studies presented at the European Society for Medical Oncology (ESMO) 2022 Congress.1,2 In the SOLO1 trial,1 more...
Expert Point of View: Suzette Delaloge, MD, MSc
Formal discussant of this study, Suzette Delaloge, MD, MSc, of Gustave Roussy, Villejuif, France, stated: “This is a big step forward and an amazing set of new knowledge. This presentation is a meaningful demonstration of the role of PM2.5 [particulate matter 2.5 µm in diameter] air pollutants in...
Research Examines a New Tool for Discovering Cancer-Driving Structural Variations
An advanced software tool for analyzing DNA sequences from tumor samples has uncovered new, likely cancer-driving genes. In a study, Weill Cornell Medicine researchers designed the software, known as CSVDriver, to map and analyze the locations of large mutations, known as structural variants, in...
Selpercatinib in RET Fusion–Positive Advanced NSCLC
As reported in the Journal of Clinical Oncology by Alexander Drilon, MD, and colleagues, an updated analysis of the multicohort phase I/II LIBRETTO-001 trial confirmed the activity of selpercatinib in patients with RET fusion–positive advanced non–small cell lung cancer (NSCLC). The trial supported ...
Association of Breast Cancer Recurrence in Patients Achieving pCR With vs Without Residual DCIS After Neoadjuvant Chemotherapy
In a retrospective analysis from the neoadjuvant I-SPY2 trial reported in JAMA Surgery, Osdoit et al found that among patients with breast cancer achieving pathologic complete response (pCR), there were no significant differences in treatment outcomes according to the presence or absence of...
Lasker Foundation Announces 2022 Lasker Award Winners
On September 28, the Lasker Foundation announced the winners of the 2022 Albert Lasker Basic Medical Research Award, the 2022 Lasker~DeBakey Clinical Medical Research Award, and the 2022 Lasker~Bloomberg Public Service Award. Albert Lasker Basic Medical Research Award Richard O. Hynes, PhD, of the...
Unhealthy Gut May Set the Stage for Breast Cancer to Spread, Preclinical Research Reveals
An unhealthy gut triggers changes in normal breast tissue that may help breast cancer metastasize, according to new, early research from the University of Virginia (UVA) Cancer Center published by Feng et al in Cancer Immunology Research. The researchers found that when the gut microbiome is...
A Physicist Father Inspired a Love of Science in Oncology Researcher Stanton L. Gerson, MD
In this installment of the Living a Full Life series, Guest Editor Jame Abraham, MD, FACP, spoke with Stanton (“Stan”) L. Gerson, MD, Dean and Senior Vice President for Medical Affairs, School of Medicine, and Acting Director of the Case Comprehensive Cancer Center and National Center for...
Diversify Cancer Clinical Trials With New Recruitment and Retention Resources
ASCO and the Association of Community Cancer Centers (ACCC) jointly released two resources to help research sites increase racial and ethnic equity, diversity, and inclusion (EDI) in cancer clinical trials. The Just ASK™ Increasing Diversity in Cancer Clinical Research: An ACCC-ASCO Training...
Determining Prognosis in Aggressive Lymphomas: Integrating Liquid Biopsy Into Imaging Assessment
The incorporation of blood-based measurements—ie, “liquid biopsies”—into imaging assessment may refine the accuracy of prognosis in aggressive lymphomas, as described by David Kurtz, MD, PhD, Assistant Professor in the Division of Oncology, Stanford University Medical Center, in a talk at the 2022...
Patients With Multiple Myeloma May Face CAR T-Cell Shortages
From microchips to automobiles, people in the United States are experiencing shortages of all kinds of products, and oncology treatments are no exception. In particular, shortages related to chimeric antigen receptor (CAR) T-cell therapy have been reported, most acutely, for B-cell maturation...
Pafolacianine for Intraoperative Imaging of Folate Receptor–Positive Ovarian Cancer
In a phase III trial reported in the Journal of Clinical Oncology, Janos L. Tanyi, MD, PhD, and colleagues found that use of pafolacianine infusion for intraoperative imaging improved the detection of lesions in patients with folate receptor–positive ovarian cancer, compared with using white light...
Reconciliation Bill Focuses on Health-Care Provisions
Update: On August 7, 2022, the Senate passed the Inflation Reduction Act (IRA), a broad climate, tax, and health-care reconciliation bill, with a vote of 51 to 50. During a review of the IRA, the Senate parliamentarian removed provisions from the bill that would have required drug companies to pay...
Researchers Find DOPA May Protect Against Melanoma and Identify Potential New Therapeutic Targets to Treat Melanoma
People with light skin tones are far more likely to develop melanoma than people with darker skin tones. This large disparity results from far more than can be explained by the ultraviolet (UV) protective effects of melanin pigment, owing in large part to the melanin precursor...
Report Finds Cancers in Adults Younger Than Age 50 Are on the Rise Globally
Over recent decades, more and more adults under the age of 50 are developing cancer. A recently published study revealed that the incidence of early-onset cancers (those diagnosed before age 50)—including breast, colon, esophageal, kidney, liver, and pancreatic cancers, among others—has...
Two New Studies Find Aggressive Prostate Cancer May Be Linked to Ancestral Heritage
Two studies published simultaneously by Jaratlerdsiri et al in Nature and Gong et al in Genome Medicine have identified genetic signatures explaining ethnic differences in the severity of prostate cancer, particularly in sub-Saharan Africa. Through genetic sequencing of prostate cancer tumors from...
Study Finds AI Ultrasound Platform Can Predict Thyroid Malignancy, Pathologic Stage, and BRAF Mutation Status
An artificial intelligence (AI) ultrasound platform that incorporates multiple methods of machine learning can accurately predict thyroid malignancy as well as pathologic and genomic outcomes, according to data presented at the 2022 Multidisciplinary Head and Neck Cancers Symposium.1 Findings from...
Study Shows AI May Improve Prediction of Colorectal Cancer Recurrence
In a multinational study using artificial intelligence (AI), investigators developed an algorithm to improve the prediction of colorectal cancer recurrence. Study results were published by Pai et al in Gastroenterology. QuantCRC Rish K. Pai, MD, PhD, a pathologist at Mayo Clinic in Arizona and...
Researchers Outline a Path to Representation in Cancer Clinical Trials
A new study published by Birhiray et al in Blood Advances outlines practical strategies for promoting diversity, equity, inclusion, and access in cancer clinical research. The study highlights significant racial disparities in cancer research, citing that between 2008 and 2018, only 7.8% of...
Proximity to Fracking Sites May Be Associated With Risk of Pediatric Leukemia
Children in Pennsylvania living near unconventional oil and gas developments at birth were two to three times more likely to be diagnosed with leukemia between the ages of 2 and 7 years than children who did not live near this oil and gas activity, after accounting for other factors that could...
Nine Oncology Practices Certified Through ASCO Patient-Centered Cancer Care Certification Pilot
ASCO recently announced that nine outpatient oncology group practices have achieved certification through the new ASCO Patient-Centered Cancer Care Certification pilot based on their adherence to oncology medical home (OMH) standards, a single set of comprehensive, expert-backed standards for...
Snapshots of Studies of Interest Presented at ASCO 2022
The 2022 ASCO Annual Meeting was filled with important science, engaging data, and several practice-changing abstracts, many of which have been covered in detail on other pages or in earlier issues of The ASCO Post. There were numerous high-impact studies and attendees, whether present at the...
Is Advance Care Planning of Any Value?
An article in The New York Times earlier this year crystallized the dilemma facing health-care providers when they are presented with a patient in a life-threatening situation: Should they rely on advance care directives written years prior to the current medical situation to accurately determine...
